TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07135323: AvertD Post-Approval Study

Sponsor: Prescient Medicine Holdings, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 4000 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07135323 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07135323 Rescue Dossier →